SillaJen: First to use lab-grown human tissue to find best cancer drug dose

South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...

SillaJen starts US trial of anti-cancer drug from Basilea

SillaJen Inc. said on Monday it has enrolled the first patient in a US phase 1 trial of an anti-cancer drug BAL0891 licensed from Swiss drugmaker Ba...

M2N to sell 52% stake in Chinese automotive parts company DKCA

M2N( DK D&I Co. ), the parent company of pharmaceutical firm Sillajen Inc., announced on Tuesday that it has signed an agreement to sell its maj...

S. Korea's SillaJen launches clinical trials in US for new anti-cancer drug

South Korean biotech company Sillajen Inc. has started recruiting patients for Phase 1 clinical trials in the US for an anti-cancer drug from a Swis...

SillaJen shares jump as exchange maintains listing, allows resumed trade

Shares in South Korea’s scandal-hit biotechnological company SillaJen Inc. soared on Thursday after the local exchange decided to maintain the...

Scandal-hit SillaJen faces higher delisting risk

South Korea's SillaJen Inc., once the largest stock on Kosdaq by market value, faces a higher risk of being kicked out of the country's junior stock...